HER2+/HR+ Breast Carcinoma Advanced Adjuvant with Neratinib

被引：0
|
作者：
Bischoff, Angelika
机构：
来源：
ONCOLOGY RESEARCH AND TREATMENT | 2020年 / 43卷 / 04期
关键词：
CANCER EXTENET; DOUBLE-BLIND; THERAPY;
D O I：
10.1159/000507534
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：180 / 180
页数：1
相关论文
共 50 条
  • [1] Position Paper on the Value of Extended Adjuvant Therapy with Neratinib for Early HER2+/HR+ Breast Cancer
    Balic, Marija
    Rinnerthaler, Gabriel
    Bartsch, Rupert
    BREAST CARE, 2021, 16 (06) : 664 - 676
  • [2] Modeling the long-term efficacy of neratinib in the extended adjuvant setting for women with HER2+/HR+ early stage breast cancer (ESBC)
    Doan, Q.
    Lalla, D.
    Yao, B.
    Danese, M.
    Barnett, B.
    Crown, J.
    BREAST, 2019, 44 : S19 - S20
  • [3] Lapatinib plus letrozole for postmenopausal patients with advanced HER2+/HR+ breast cancer
    Guarneri, Valentina
    EXPERT REVIEW OF ANTICANCER THERAPY, 2009, 9 (11) : 1549 - 1557
  • [4] HER2+/HR+ breast cancer patients at high risk of relapse derive benefit from extended adjuvant treatment with neratinib: An exploratory analysis from ExteNET study
    Cognetti, F.
    Di Cosimo, S.
    Bruzzi, P.
    Caprari, F.
    Dapretto, E.
    Trouiller, J-B.
    Valenti, R.
    Pronzato, P.
    ANNALS OF ONCOLOGY, 2021, 32 : S420 - S420
  • [5] Treatment of HER2+/HR+ early breast cancer with neratinib: selected patient cases from a retrospective single case report retrieval project
    Baerens, D. -t.
    Guth, D.
    Goehler, T.
    Janni, W.
    Pluschnig, U.
    Zahn, M. -o.
    Wuerstlein, R.
    Vannier, C.
    Maass, N.
    Petru, E.
    BREAST, 2025, 80
  • [6] How to Optimise Extended Adjuvant Treatment with Neratinib for Patients with Early HER2+ Breast Cancer
    Michael Untch
    Miguel Martin
    Michelino De Laurentiis
    Joseph Gligorov
    Oncology and Therapy, 2021, 9 : 297 - 309
  • [7] How to Optimise Extended Adjuvant Treatment with Neratinib for Patients with Early HER2+ Breast Cancer
    Untch, Michael
    Martin, Miguel
    de Laurentiis, Michelino
    Gligorov, Joseph
    ONCOLOGY AND THERAPY, 2021, 9 (02) : 297 - 309
  • [8] The potential markers of endocrine resistance among HR+ /HER2+ breast cancer patients
    K. Chen
    J. Quan
    J. Yang
    Z. Chen
    Clinical and Translational Oncology, 2020, 22 : 576 - 584
  • [9] The Synergistic Effects of SHR6390 Combined With Pyrotinib on HER2+/HR+ Breast Cancer
    Wang, Yukun
    Yuan, Xiang
    Li, Jing
    Liu, Zhiwei
    Li, Xinyang
    Wang, Ziming
    Wei, Limin
    Li, Yuanpei
    Wang, Xinshuai
    FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY, 2021, 9
  • [10] Comparison of ctDNA profiles from HR+/HER2-low and HR+/HER2-0 advanced breast cancer patients
    Dobric, N.
    Dandachi, N.
    Klocker, E. V.
    Suppan, C.
    Graf, R.
    Hasenleithner, S.
    Jost, P. J.
    Heitzer, E.
    Balic, M.
    ANNALS OF ONCOLOGY, 2023, 34 : S387 - S387
12345